such patients; as ofthe end ofFebruary 1993, we had diagnosed and treated another 67 cases (bringing to 91 the total of such patients at this hospital). We report our experience with this group of patients at a single institution.
Methods
Careful review of discharge diagnoses, the microbiology laboratory's culture findings, the logs of anatomical pathology findings, and consultation books of the infectious diseases and pulmonary medicine services from 1982 through February 1993 yielded a total of91 patients whose records were available and who had HIV infection with coccidioidomycosis.
The diagnosis of coccidioidomycosis was based on (1) culture of C. immitis from respiratory secretions or other biological material, (2) recognition of the organism in either histopathologic or Papanicolaou-stained cytological specimens, or (3) the positivity of coccidioidal serologies in the setting of a compatible clinical illness.
The diagnosis of HIV infection was established with the use of an ELISA and was confirmed by western blotting. Before the availability of techniques for measurement of antibody to HIV, AIDS was diagnosed if patients belonged to a high-risk group (i.e., homosexual or bisexual males, intravenous drug users, or recipients of blood or blood products) and had either Kaposi's sarcoma or an opportunistic infection that was recognized by the Centers for Disease Control and Prevention as an AIDS-defining illness, without another recognizable cause of immunosuppression.
Pertinent clinical information was obtained from review of the patients' hospital charts and other appropriate records. The dates of death were obtained from either the clinical records or the registry of deaths. Survival data were analyzed with the software package SPSS (Statistical Procedure for the Social Sciences; SPSS, Chicago). Survival rates were calculated from the date ofinitial diagnosis, and the method of Kaplan-Meier was used to estimate the survival function.
The McNemar test, the sign test, and the Wilcoxon matchedpair signed-rank test provided the basis for the Student's t-test and the cumulative incidence with 95% confidence intervals. In all cases, a P value of <.05 was considered to indicate statistical significance. Logistic regression analysis was performed to predict mortality, and a probability of >0.5 was considered significant.
Results
A total of 91 patients with concomitant coccidioidomycosis and HIV infection were identified. The number of patients with dual infection increased from one in 1982 to 19 in 1991. Eight new patients were identified in only the first 2 months of 1993 (figure 1). Coccidioidomycosis was the AIDS-defining illness for 37 patients. Opportunistic infections that were concomitant with coccidioidomycosis were infrequent and hence not reported separately.
The demographic characteristics of the patients are shown in table 1.
Presenting Clinical Features Table 2 shows the most common symptoms at the time of initial presentation. Fever and chills, cough, and weight loss occurred in most of the patients, while night sweats were noted by more than one-third. Other, less frequent complaints included fatigue, diarrhea, shortness of breath, and headache. Palpable, large lymph nodes were found in 22 patients (24%), and seven (8%) also had a palpable spleen. noted to be a common presentation of cocc idioido mycosis in patients with AIDS [4] . Focal abn orm aliti es (a discrete nodule or infiltra te, one or more cavity, pleural eff usion, or hilar adenopath y) were seen on the chest radiog raphs of 13 pati ents (14 % ). The films were negative fur 15 pa tients (16 % ), and thos e of four patients could not be located . Amo ng the 13 patients w ith a focal abn ormal ity evi dent on the ches t rad iograph , two had cocci dioidal meningitis as the only ex trapulmo nary invol vem ent. In the rem ainin g II pati ents the disease was limit ed to the chest. Of the 15 patie nts whose chest rad iographs were norm al on presentation, 4 had menin gitis, 2 had coccidioidomycosis in lymph nodes, and I eac h had C. immitis in the laryn x, eye , skin, and uri ne (iso lated from spec ime ns); the other 5 we re serologica lly positive for cocc idioido mycosis and had a co mpa tible clinical illness. Three of the four pat ient s whose radio graphs we re not avai lable were only serologically po sitive, while the rema ining pat ient' s sputu m culture and liver biop sy we re posit ive for C. immitis.
Extent of the Disease
The lung was the most commonly invo lved organ. Seventythree patients (80%) had pulmonary involvement, including one pati ent whose ch est radi ograph was not a vailabl e but whose sputum culture was positi ve. The meninges we re invol ved in 14 pa tients ( 15%) . Various othe r sites wer e also involved, incl uding lymp h nodes, skin, liver, ge nitourinary system, eye , spleen, heart, and laryn x. One patie nt 's blood cul ture was positive.
CD4 Lymphoc yte Counts
Th e CD4 and CDS lym phocyte co unts were determined for 60 patients (66%) close to the time of diagnosis of coccidioidomycosis. Patient s with diffuse disease had a stati sticall y significant (P < .05: Student's r-test) lower mean CD4 ly mphocy te count (.055 X lO9/L) than did pat ients who had foc al disease (. 127 X 109/L) or whose ch est rad iograph was normal at presentation (.095 X 10'l/L) .
Pati ents with Coccidioidal Meningitis
A total of 14 patients ( 15' %) had cocci dioidal men ingitis. Eight of these pat ien ts (57 %) present ed with diffu se pulm onary invo lveme nt, and 2 ( 13%) had foca l pulm on ary disease. Fo ur patient s presented with me ning itis alone, without any obvious pulm onary or othe r orga n invo lveme nt, Afte r the term ination of our review. men ingeal involvem ent occ urred ill two additio nal patients while they were receiving therap y for diffuse pulm onary cocci dio idomycosis .
Diagnostic Method s
While no defined pro tocol was followed, diagno sti c eva luation gene rally pro ceed ed from nonin vasive tests to tests that wer e more and more invasive, culminating in biopsy of the lung. This stepw ise progression did not occur when patient s were critically ill on admi ssion . In the se patients , diagnostic bron choscop y with bronchoalveolar lava ge (BAL) and tran sbronchia l biopsy were frequently thc first tests.
Sero logical tests for antibodies to C. immit is were performed in a sing le reference labor atory (State of Arizo na Laboratory ) for 88 pati ents. The mainstay of serologic al diagn osis was the C F test, which was performed 0 11 most pati ents. During the ea rly 1980s the tube precipitati on test wa s used by the reference laboratory , but later thi s test was replaced by a simple doubl eimmuno diffusion test.
For 60 patients (68%) one or more serolog ical tests were positive , while all serological tests we re nega tive for 2 1 (23 %) , of whom I 7 had diffuse pulmonary disease. The CF test wa s an tico mplementary for seve n patient s (9%) . Th ese seve n patien ts did not have the doubl e-immun odiffusion test perform ed on their sera, so their ability to form cocc idioidal antib odi es was undetermined.
Serologi cal tests played an important role in diagnosis for our patients. For 20 pati ents (2 1%) , a pos itive sero logical tes t was the first and (frequently) the only ev ide nce of coccidioidom ycosis, Nin e of the se 20 patients had diffuse pulmonar y di s-em 1996;23 (September) ease (CF titer, > 1:64). Three other patients had focal pulmonary disease (CF titers: 1:256, 1:8, and 1:8, respectively). Five additional patients had normal chest radiographs: 2 had meningitis, 2 had a CF titer of> 1:128, and 1 had a low titer of 1:8. The remaining three patients' chest radiographs were not available, and their positive CF titer was the only evidence of coccidioidomycosis. Follow-up serologies were not done routinely.
Since respiratory symptoms predominated and chest radiographic abnormalities occurred in the majority of the patients, evaluation of respiratory secretions was performed in most cases (table 4) . When expectorated sputum was available, it was studied first. If a patient was unable to produce sputum and induced sputum could not be obtained, bronchoscopy with BAL was performed.
Approximately two-thirds of the respiratory secretions were positive, either by cultural recovery of the fungus or by direct visualization ofthe organism on Papanicolaou-stained cytological preparations. Both methods failed to confirm the suspected diagnosis for 14 patients, and these patients underwent repeated bronchoscopy with transbronchial biopsy.
Transbronchial biopsy specimens from all 14 patients (13 of whom had diffuse disease) were histopathologically positive, while only 8 of the 10 specimens that were submitted for culture yielded C. immitis. It is not surprising that patients with diffuse pulmonary disease underwent bronchoscopy frequently. Of the 48 patients whose BAL fluid was examined cytologically, 44 had diffuse disease. BAL fluid cultures were performed for 42 patients, of whom 41 had diffuse pulmonary disease, and 29 (69%) of the cultures were positive for C. immitis.
Skin Tests
Evaluable data from intradermal skin tests were recorded for only 30 patients. The skin test was negative at 48 -72 hours for 28 (93%), and 21 ofthese 28 patients had diffuse pulmonary disease.
Therapy
Administration of intravenous amphotericin B (AmB) was the primary therapy. Generally, a l-mg test dose of intravenous ArnE was given, and if no difficulties were encountered, a further 20-mg dose was infused. The dosage of AmB was rapidly increased to 50 mg daily. The goal of therapy was to administer at least 1.5-2.5 g of AmB as rapidly as renal function allowed. Overall, 66 patients (72%) received systemic AmB.
Of the 59 patients with diffuse pulmonary disease, 32 received AmB alone (mean dose, 1,093 mg); 17 patients received AmB (mean dose, 1,352 mg) and then oral ketoconazole (7) or fluconazole (10); 3 patients received oral fluconazole alone; 6 patients received no antifungal treatment (1 refused treatment, 3 died within 3 days of the diagnosis of coccidioidomycosis, and 2 died within 3 weeks of the diagnosis); and 1 patient's therapy was not known.
Of the remaining 32 patients, whose chest radiographs were unavailable or revealed only focal or no abnormalities, 4 received AmB alone; 13 patients received ArnE and then oral fluconazole (8) or ketoconazole (5); 11 patients received oral azoles alone (fluconazole, 10; ketoconazole, 1); and 4 did not receive any treatment. Among 14 patients with meningitis, 4 were treated with intrathecal and intravenous AmB; 7 with intrathecal and intravenous AmB and then oral fluconazole (5) or ketoconazole (2); 2 with oral ketoconazole alone; and 1 with fluconazole alone.
Outcome At the conclusion of this review at the end of February 1993, 55 of the 91 patients (60%) had died, 27 were alive, and 9 were lost to follow-up (but were alive at the last follow-up). The mean duration of survival for the 55 patients was 246 days (range, 0-1,51 0 days), and the median was 95 days; the duration of their survival was analyzed in relation to chest radiographic findings on admission (figure 3).
Forty (68%) of 59 patients with diffuse pulmonary coccidioidomycosis died, after a median duration of survival of 54 days. The duration of survival among patients with diffuse pulmonary disease was significantly shorter (P < .05; 95% CI, 147-175 days) than among patients with focal disease (median, 188 days) or among patients whose chest radiographs were normal (median, 644 days).
A meaningful analysis to assess the impact of AmB on mortality and a comparison of azoles to AmB could not be performed. Logistic regression analysis was carried out to predict the involvement of probability in mortality. A probability of >0.5 was considered significant and likely to predict death. The presence of diffuse pulmonary disease and a CD4 lympho- monia. In the early years of the study period, P. carinii pneumonia was the most frequent preliminary diagnosis. However, with experience we began to recognize that evidence of diffuse reticulonodular infiltrates on the chest radiographs of HIVinfected persons from areas in which C. immitis is endemic is a characteristic clinical picture suggesting the high likelihood of active coccidioidomycosis. This pattern of diffuse pulmonary disease in patients with HIV infection and coccidioidomycosis has been noted by others as well [8, 11] . A prospective study of coccidioidomycosis during HTVinfection in an area in which the disease is endemic also showed that of the 13 subjects who had active coccidioidomycosis during the study, five (45%) had diffuse pulmonary infection [14] .
From our experience and that in other series [7] [8] [9] [10] [11] 14] , it is clear that almost two-thirds of HIV-infected patients with active coccidioidomycosis present with a distinct, characteristic radiographic presentation of diffuse reticulonodular pulmonary infiltrates (figure 2). Other manifestations of coccidioidomycosis, such as focal pulmonary disease, meningitis, and skin or lymph node involvement, are not dissimilar from those in non-HIV-infected patients.
Serologies are generally the first diagnostic tests to he performed and play an important role in the diagnosis [15] . Unfortunately, for many sick patients all attempts at serodiagnosis will fail. In these patients, because of the serious nature and rapid pace of the disease, invasive procedures such as BAL or trans bronchial biopsy for cytology and culture are frequently needed. In our study CF was the most commonly performed serological test, but both tube precipitation and immunodiffusion tests were also performed for some patients.
It is important to note that for 20 (21%) of the 88 patients for whom serological tests were performed, all such tests were negative. Seventeen (85%) of these 20 patients whose coccidioidal serologies were negative had diffuse pulmonary disease, and all these patients underwent bronchoscopy to establish the diagnosis of coccidioidomycosis. The absence of a serological response in patients with diffuse pulmonary disease has been noted previously [11] and may be due to profound immunosuppression as a result of advanced HIV infection. Therefore, these patients' failure to mount an antibody response was not a surprise.
Intradermal skin testing is of little value in establishing the diagnosis. Thirty patients were tested with intradermal coccidioidin, and only two (6%) had a positive response. Most of the 28 nonreacting patients had diffuse pulmonary disease.
Our experience has shown that serological tests (tube precipitation, CF, and immunodiffusion) can provide useful diagnostic information and should be performed for all HIV -infected patients suspected of having coccidioidomycosis. However, given that a substantial number of patients with severe diffuse pulmonary disease will be serologically negative, it is important not to rely solely on serological testing for diagnosis or for evaluating response to therapy in this setting. Unfortunately, the turnaround time for most serological tests is several days, and one Coccidioidal infection is either asymptomatic or produces subacute respiratory symptoms in immunocompetent hosts [1, 3] . Fungemia, diffuse pulmonary involvement, or extrathoracic infections are most frequently found in immunosuppressed patients and are rare in otherwise healthy hosts [6, 12, 13] . Thus, given the profound immunosuppression in HIVinfected patients, active (often severe and disseminated) coccidioidomycosis is to be expected [7, 11] . In this retrospective study we reviewed our experience of coccidioidomycosis in HIV-infected patients over an l l-year period at a single institute.
The demographic characteristics of the patients in this series in general are similar to those seen in other studies of HIVinfected persons. The racial distribution is a reflection of the ethnic composition of the Phoenix metropolitan area and does not necessarily represent an increased risk for coccidioidomycosis among black or Hispanic HIV-infected patients. In 37 patients (41%) coccidioidomycosis was the AIDS-defining illness, a finding that highlights the importance of coccidioidomycosis as a significant opportunistic infection among HIVinfected patients in areas of endemicity (an observation that has been substantiated by other investigators [8, 11D. We found that a substantial number (65%) of HIV-infected patients with coccidioidal infection presented with diffuse pulmonary disease. The signs and symptoms in this group of patients were nonspecific, frequently mimicking other opportunistic pulmonary infections such as Pneumocystis carinii pneu-may not be able to wait that long. Therefore, for critically ill patients with diffuse pulmonary disease from whom expectorated sputum cannot be obtained, urgent bronchoscopy with BAL should be performed for rapid diagnosis.
Active coccidioidomycosis is more likely to develop in patients with a CD4 lymphocyte count of <0.250 X 10 9/L [7, 11, 14] . Among our patients the median CD4 lymphocyte count was <0.100 X 10 9 /1. Patients with a median CD4 lymphocyte count of <0.050 X 109/L had the highest mortality (P < .05) and were more likely to have diffuse pulmonary disease.
The extent of the disease has a direct association with outcome. Patients with diffuse pulmonary disease lived for a much shorter duration (median, 54 days) than did those with focal pulmonary involvement or no abnormalities evident on chest radiographs. This high mortality among patients with diffuse pulmonary coccidioidomycosis has been observed in two retrospective studies [7, II] as well as one prospective study [14] . Development of meningeal disease also carried a grave prognosis: >90% of our patients with meningeal disease died of their illness.
There are no established guidelines for the treatment of coccidioidomycosis in HIV-infected patients. Most clinicians in areas of endemicity believe that AmB should be administered to most acutely ill patients and that it should be given at the highest tolerable doses [16, 17] . The majority of our patients received AmB initially, followed by therapy with oral ketoconazole or fluconazole.
Although fluconazole appears to be effective as therapy for coccidioidomycotic meningitis in both patients who were infected with HIV and those who were not [18] , most of our patients were treated before this information was available. Eleven of our 14 patients with meningitis were treated with both intravenous and intrathecal AmB, and we do not have enough experience with fluconazole to draw a meaningful comparison. Although the optimal therapy for coccidioidomycosis in HIV-infected patients is unclear, lifelong systemic antifungal therapy following treatment of acute disease is recommended [17] .
Among HIV-infected patients living in an area of endemicity, coccidioidomycosis is an important opportunistic infection that causes substantial morbidity and mortality. In our experience, coccidioidomycosis is frequently the AIDS-defining illness. Because of the great mobility of this population, it will not be unusual for HIV-infected patients to present with coccidioidomycosis well outside the areas in which it is endemic.
Physicians managing the care of patients with HIV infection should consider coccidioidomycosis in the differential diagnosis of diffuse lung disease or meningitis and should carefully document any residence in or travel to areas of endemicity. Appropriate serologies, culture, and histologic examination of biopsy material should be performed for such patients.
